Journal article
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study
Anti-cancer drugs, Vol.26(8), pp.878-883
09/2015
DOI: 10.1097/CAD.0000000000000254
PMID: 26053279
Abstract
The primary objective of this study was to determine the activity and safety of carboplatin, methotrexate, vinblastine, and epirubicin (the M-VECa regimen) in patients with advanced bladder cancer after failure of at least one chemotherapy line. Treatment consisted of carboplatin 250mg/m(2) on day 1, methotrexate 30mg/m(2) on days 1 and 22, vinblastine 3mg/m(2) on days 2 and 22, and epirubicin 50mg/m(2) on day 2 every 28 days until disease progression or death. Response rate was the main end-point. Twenty-five patients were enrolled: the median age was 67 years (range 42-83) and there were 14 patients aged at least 70 years (56%). Fourteen patients had previously received vinflunine as a second-line treatment. Complete remission occurred in one patient (4%), partial remission in five patients (20%), and stable disease in eight patients (32%). The overall response rate was 24% [95% confidence interval (CI), 9.3-45.1%] and the overall disease control rate was 56% (95% CI, 34.9-75.5%). The median progression-free survival was 5.1 months (95% CI, 3.9-6.4) and the median overall survival was 9.5 months (95% CI, 7.1-11.2). Treatment was well tolerated: grade 3 neutropenia was documented in five patients and grade 3 nausea and vomiting in two patients. The M-VECa regimen seems to be feasible as second-line or third-line treatment in patients with advanced bladder cancer who have been pretreated with one or more chemotherapy lines, and may achieve encouraging results in terms of disease control rate, progression-free survival, and overall survival. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
Details
- Title: Subtitle
- Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study
- Creators
- Roberto Petrioli - University of SienaGiandomenico Roviello - University of SienaAnna Ida Fiaschi - University of SienaLetizia Laera - University of SienaSalvatora Tindara Miano - University of SienaVincenzo Bianco - Policlinico Umberto IEdoardo Francini - Policlinico Umberto I
- Resource Type
- Journal article
- Publication Details
- Anti-cancer drugs, Vol.26(8), pp.878-883
- DOI
- 10.1097/CAD.0000000000000254
- PMID
- 26053279
- NLM abbreviation
- Anticancer Drugs
- ISSN
- 0959-4973
- eISSN
- 1473-5741
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 6
- Language
- English
- Date published
- 09/2015
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221146402771
Metrics
2 Record Views